134 related articles for article (PubMed ID: 14566205)
1. Advances in recognition and treatment of social anxiety disorder: a 10-year retrospective.
Stein MB
Psychopharmacol Bull; 2003; 37 Suppl 1():97-107. PubMed ID: 14566205
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine.
Allgulander C; Mangano R; Zhang J; Dahl AA; Lepola U; Sjödin I; Emilien G;
Hum Psychopharmacol; 2004 Aug; 19(6):387-96. PubMed ID: 15303242
[TBL] [Abstract][Full Text] [Related]
3. Paroxetine treatment of mood and anxiety disorders in children and adolescents.
Wagner KD
Psychopharmacol Bull; 2003; 37 Suppl 1():167-75. PubMed ID: 14566209
[TBL] [Abstract][Full Text] [Related]
4. The nature of social anxiety disorder.
Westenberg HG
J Clin Psychiatry; 1998; 59 Suppl 17():20-6. PubMed ID: 9811426
[TBL] [Abstract][Full Text] [Related]
5. Retrospective reports of parenting in depressed adults with and without comorbid panic disorder and social anxiety disorder.
Torpey DC; Olino TM; Klein DN
J Nerv Ment Dis; 2007 Sep; 195(9):738-44. PubMed ID: 17984773
[TBL] [Abstract][Full Text] [Related]
6. How is recovery from social anxiety disorder defined?
Bobes J
J Clin Psychiatry; 1998; 59 Suppl 17():12-9. PubMed ID: 9811425
[TBL] [Abstract][Full Text] [Related]
7. Comorbidity, neurobiology, and pharmacotherapy of social anxiety disorder.
Pollack MH
J Clin Psychiatry; 2001; 62 Suppl 12():24-9. PubMed ID: 11430615
[TBL] [Abstract][Full Text] [Related]
8. How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database.
Baldwin DS; Stein DJ; Dolberg OT; Bandelow B
Hum Psychopharmacol; 2009 Jun; 24(4):269-75. PubMed ID: 19334042
[TBL] [Abstract][Full Text] [Related]
9. Escitalopram in the treatment of social anxiety disorder: analysis of efficacy for different clinical subgroups and symptom dimensions.
Stein DJ; Kasper S; Andersen EW; Nil R; Lader M
Depress Anxiety; 2004; 20(4):175-81. PubMed ID: 15643634
[TBL] [Abstract][Full Text] [Related]
10. An epidemiologic perspective on social anxiety disorder.
Stein MB
J Clin Psychiatry; 2006; 67 Suppl 12():3-8. PubMed ID: 17092189
[TBL] [Abstract][Full Text] [Related]
11. Changes on the Temperament and Character Inventory after paroxetine treatment in volunteers with generalized anxiety disorder.
Allgulander C; Cloninger CR; Przybeck TR; Brandt L
Psychopharmacol Bull; 1998; 34(2):165-6. PubMed ID: 9640994
[TBL] [Abstract][Full Text] [Related]
12. Comorbidity in social anxiety disorder: impact on disease burden and management.
Lecrubier Y
J Clin Psychiatry; 1998; 59 Suppl 17():33-8. PubMed ID: 9811428
[TBL] [Abstract][Full Text] [Related]
13. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
14. Social anxiety symptoms across diagnoses among outpatients attending a tertiary care mood and anxiety disorders service.
Graystone HJ; Garner MJ; Baldwin DS
J Affect Disord; 2009 Apr; 114(1-3):305-9. PubMed ID: 18656267
[TBL] [Abstract][Full Text] [Related]
15. Social anxiety disorder: etiology and early clinical presentation.
Beidel DC
J Clin Psychiatry; 1998; 59 Suppl 17():27-32. PubMed ID: 9811427
[TBL] [Abstract][Full Text] [Related]
16. Incidence of social anxiety disorder and the consistent risk for secondary depression in the first three decades of life.
Beesdo K; Bittner A; Pine DS; Stein MB; Höfler M; Lieb R; Wittchen HU
Arch Gen Psychiatry; 2007 Aug; 64(8):903-12. PubMed ID: 17679635
[TBL] [Abstract][Full Text] [Related]
17. The Kutcher Generalized Social Anxiety Disorder Scale for Adolescents: assessment of its evaluative properties over the course of a 16-week pediatric psychopharmacotherapy trial.
Brooks SJ; Kutcher S
J Child Adolesc Psychopharmacol; 2004; 14(2):273-86. PubMed ID: 15319024
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of controlled-release paroxetine.
Golden RN
Psychopharmacol Bull; 2003; 37 Suppl 1():176-86. PubMed ID: 14566210
[TBL] [Abstract][Full Text] [Related]
19. Social anxiety disorder as a hidden psychiatric comorbidity among cancer patients.
Akechi T; Okuyama T; Sagawa R; Uchida M; Nakaguchi T; Ito Y; Furukawa TA
Palliat Support Care; 2011 Mar; 9(1):103-5. PubMed ID: 21352622
[TBL] [Abstract][Full Text] [Related]
20. Comorbidity of generalized social anxiety disorder and depression in a pediatric primary care sample.
Chavira DA; Stein MB; Bailey K; Stein MT
J Affect Disord; 2004 Jun; 80(2-3):163-71. PubMed ID: 15207929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
